Who are Low dose nadroparin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dalteparin (Fragmin), High Dose Enoxaparin, Hepalean Heparin, Innohep (tinzaparin), Enoxaparin Injectable Solution, Intermediate dose nadroparin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/low-dose-nadroparin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Low dose nadroparin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Low dose nadroparin (Low dose nadroparin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Low-molecular-weight heparin (LMWH). Area: Cardiovascular.

marketed Low-molecular-weight heparin (LMWH) Factor Xa, Thrombin (Factor IIa) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Low dose nadroparin (Low dose nadroparin) — Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA). Low-dose nadroparin is a low-molecular-weight heparin that inhibits blood coagulation by enhancing the activity of antithrombin III against factor Xa and thrombin.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Low dose nadroparin TARGET	Low dose nadroparin	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	marketed	Low-molecular-weight heparin (LMWH)	Factor Xa, Thrombin (Factor IIa)
Dalteparin (Fragmin)	Dalteparin (Fragmin)	M.D. Anderson Cancer Center	marketed	Low-molecular-weight heparin (LMWH)	Antithrombin III (indirect target); Factor Xa and Factor IIa (thrombin)
High Dose Enoxaparin	High Dose Enoxaparin	Oregon Health and Science University	marketed	Low-molecular-weight heparin (LMWH)	Coagulation factors Xa and IIa (via antithrombin III)
Hepalean Heparin	Hepalean Heparin	McMaster University	marketed	Low-molecular-weight heparin (LMWH)	Antithrombin III (indirect target); Factors Xa and IIa
Innohep (tinzaparin)	Innohep (tinzaparin)	Ottawa Hospital Research Institute	marketed	Low-molecular-weight heparin (LMWH)	Factor Xa and thrombin (via antithrombin III enhancement)
Enoxaparin Injectable Solution	Enoxaparin Injectable Solution	Medical University of Vienna	marketed	Low-molecular-weight heparin (LMWH)	Antithrombin III (indirect); Coagulation factors Xa and IIa
Intermediate dose nadroparin	Intermediate dose nadroparin	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	marketed	Low-molecular-weight heparin (LMWH)	Factor Xa, Thrombin (via antithrombin III enhancement)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Low-molecular-weight heparin (LMWH) class)

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · 7 drugs in this class
University of Melbourne · 3 drugs in this class
French Cardiology Society · 2 drugs in this class
Ottawa Hospital Research Institute · 2 drugs in this class
McMaster University · 2 drugs in this class
Assistance Publique - Hôpitaux de Paris · 2 drugs in this class
GlaxoSmithKline · 1 drug in this class
IRCCS Azienda Ospedaliero-Universitaria di Bologna · 1 drug in this class
Cristália Produtos Químicos Farmacêuticos Ltda. · 1 drug in this class
Helsinki University Central Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Low dose nadroparin — Competitive Intelligence Brief. https://druglandscape.com/ci/low-dose-nadroparin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing